Who
Eric Easom
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, AN2 Therapeutics.
In numbers
- Trades disclosed
- 51
- Buys
- 3
- Sells
- 17
- Bought
- $115K
- Sold
- $1.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 29 Mar 2022
- Last trade
- 19 Mar 2026
- Last filed
- 23 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —249,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —249,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —249,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —249,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —225,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —267,650 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —267,650 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —225,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —267,650 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —267,650 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —112,250 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —224,500 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —224,500 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —112,250 at $0.00 | filing |
| 2 Jun 2025filed 3 Jun 2025 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K10,000 at $1.07 | filing |
| 26 Feb 2025filed 28 Feb 2025 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —290,500 at $0.00 | filing |
| 26 Feb 2025filed 28 Feb 2025 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —145,250 at $0.00 | filing |
| 18 Nov 2024filed 18 Nov 2024 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K50,000 at $1.00 | filing |
News
No headline names them, or the companies they trade most, lately.